REFERENCES

1. Kamei S, Morita A, Serizawa K, Mizutani T, Hirayanagi K. Quantitative EEG analysis of executive dysfunction in Parkinson disease. J Clin Neurophysiol Off Publ Am Electroencephalogr Soc 2010; 27(3): 193–7.
2. Caviness JN, Hentz JG, Evidente VG, et al. Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson’s disease. Parkinsonism Relat Disord 2007; 13(6): 348–54.
3. Stoffers D, Bosboom JLW, Deijen JB, Wolters EC, Berendse HW, Stam CJ. Slowing of oscillatory brain activity is a stable characteristic of Parkinson’s disease without dementia. Brain 2007; 130(7): 1847–60.
4. Darcourt J, Schiazza A, Sapin N, et al. 18F-FDOPA PET for the diagnosis of parkinsonian syndromes. Q J Nucl Med Mol Imaging Off Publ Ital Assoc Nucl Med [and] Int Assoc Radiopharmacol (IAR), [and] Sect Soc of. 2014; 58(4): 355–65.
5. Ibrahim N, Kusmirek J, Struck AF, et al. The sensitivity and specificity of F-DOPA PET in a movement disorder clinic. Am J Nucl Med Mol Imaging 2016; 6(1): 102–9.
6. Morrish PK, Sawle G V, Brooks DJ. Clinical and [18F] dopa PET findings in early Parkinson’s disease. J Neurol Neurosurg Psychiatry 199; 59(6): 597–600.
7. Strafella AP, Bohnen NI, Perlmutter JS, et. al. Molecular imaging to track Parkinson’s disease and atypical parkinsonisms: New imaging frontiers. Mov Disord. 2017 Feb; 32(2): 181–192.
8. Kehagia AA, Barker RA, Robbins TW. Cognitive Impairment in Parkinson’s Disease: The Dual Syndrome Hypothesis. Neurodegener Dis 2013; 11(2): 79–92.
9. Martinez-Martin P, Rodriguez-Blazquez C, Alvarez-Sanchez M, et al. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). J Neurol. 2013; 260(1): 228–36.
10. Delorme A, Mullen T, Kothe C, et al. EEGLAB, SIFT, NFT, BCILAB, and ERICA: New tools for advanced EEG processing. Comput Intell Neurosci. 2011.
11. Koessler L, Maillard L, Benhadid A, et al. Automated cortical projection of EEG sensors: Anatomical correlation via the international 10–10 system. Neuroimage 2009; 46(1): 64–72.
12. Siemionow V, Yue GH, Ranganathan VK, Liu JZ, Sahgal V. Relationship between motor activity-related cortical potential and voluntary muscle activation. Exp brain Res. 2000; 133(3): 303–11.
13. Yao WX, Ranganathan VK, Allexandre D, Siemionow V, Yue GH. Kinesthetic imagery training of forceful muscle contractions increases brain signal and muscle strength. Front Hum Neurosci. 2013; 7(SEP): 1–6.
14. Siderowf A. Schwab and England Activities of Daily Living Scale. In: Kompoliti K, Metman LVBT-E of MD, editors. Oxford: Academic Press, 2010, pp 99–100.
15. Arbuthnott K, Frank J. Trail making test, part B as a measure of executive control: validation using a set-switching paradigm. J Clin Exp Neuropsychol. 2000; 22(4): 518–28.
16. Sánchez-Cubillo I, Periáñez JA, Adrover-Roig D, et al. Construct validity of the Trail Making Test: role of task-switching, working memory, inhibition/interference control, and visuomotor abilities. J Int Neuropsychol Soc. 2009; 15(3): 438–50.
17. Zalonis I, Christidi F, Bonakis A, et al. The stroop effect in Greek healthy population: normative data for the Stroop Neuropsychological Screening Test. Arch Clin Neuropsychol Off J Natl Acad Neuropsychol. 2009; 24(1): 81–8.
18. Egner T, Hirsch J. The neural correlates and functional integration of cognitive control in a Stroop task. Neuroimage. 2005; 24(2): 539–47.
19. Rinne OJ, Nurmi E, Ruottinen HM, Bergman J, Eskola O, Solin O. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson’s disease. Synapse. 2001; 40(3): 193–200.
20. Stormezand GN, Chaves LT, Vállez García D, et al. Intrastriatal gradient analyses of 18F-FDOPA PET scans for differentiation of Parkinsonian disorders. NeuroImage Clin. 2020; 25: 102161.
21. Hirano S. Clinical implications for dopaminergic and functional neuroimage research in cognitive symptoms of Parkinson’s disease. Mol Med. 2021 Apr 15;27(1):40. doi: 10.1186/s10020-021-00301-7. PMID: 33858320; PMCID: PMC8048076.
22. Ma Y, Dhawan V, Mentis M, Chaly T, Spetsieris PG, Eidelberg D. Parametric mapping of [18F]FPCIT binding in early stage Parkinson’s disease: a PET study. Synapse. 2002 Aug;45(2):125-33. doi: 10.1002/syn.10090. PMID: 12112405.
23. Rinne JO, Portin R, Ruottinen H, Nurmi E, Bergman J, Haaparanta M, Solin O. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. Arch Neurol. 2000 Apr;57(4):470-5. doi 10.1001/archneur.57.4.470. PMID: 10768619.